Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

Aug 15 2019

• By Michael Cipriano

Tuberculosis

Related Content

LPAD As An Afterthought? Insmed’s Arikayce Reaches US Market Thanks To Limited Population Pathway

Oct 03 2018

Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis

Jun 07 2019

TB Alliance's Pretomanid Seems OK Heading To Advisory Cmte. As US FDA Showcases Regulatory Flexibility

Jun 05 2019

Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Jun 27 2018

Related Companies

Global Alliance for TB Drug Development

Johnson & Johnson

Pfizer Inc.

Insmed Incorporated

Achaogen, Inc.

Viatris Inc.

Additional Topics

United States Approvals Review Pathway Regulation Infectious Diseases BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window